Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs

Core Insights - Innocan Pharma Corporation has published a research article demonstrating the efficacy, pharmacokinetics, and safety of liposomal synthetic cannabidiol (LPT-CBD) in dogs, specifically for pain management in osteoarthritis [1][2][3]. Study Findings - The study involved eight client-owned dogs with naturally occurring osteoarthritis, who received two subcutaneous injections of LPT-CBD (7 mg/kg) and a placebo in a randomized, blinded, crossover design [2]. - Significant improvements were observed in behavior and function, with 100% of dogs showing improved function after LPT-CBD compared to 25% after placebo (p = 0.0217) [7]. - There was a notable reduction in lameness (p = 0.033) and pain (p = 0.005) following LPT-CBD administration compared to placebo [7]. - The sustained-release profile of LPT-CBD resulted in measurable plasma CBD concentrations lasting up to four weeks post-injection [7]. Expert Commentary - Professor Chezy Barenholz highlighted the importance of this study, noting the clear advantages of LPT-CBD over the placebo [4]. - Dr. Eyal Kalo expressed optimism regarding LPT-CBD's potential for long-acting pain management in both veterinary and human applications, mentioning ongoing discussions with the FDA [4]. Company Overview - Innocan Pharma is an innovator in pharmaceuticals and wellness, developing a CBD-loaded liposome drug delivery platform for non-opioid pain management [8].